var path='https://www.tickertech.net'; function heading(heading) { document.write('

'+ ''+ '
• '+heading+'
'+ ''+ '

'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('

\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
4/26 - 8:30 AM \; \;Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
4/23 - 7:01 AM \; \;Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
4/22 - 4:11 AM \; \;Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
4/18 - 7:00 PM \; \;U.S. FDA Approves Subcutaneous Administration of Takeda\'s ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn\'s Disease
4/8 - 8:00 AM \; \;Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
3/27 - 8:55 AM \; \;Empathy in Action: Takeda\'s Global Initiative Brings IBD Challenges to the Forefront in the UAE
3/26 - 7:07 PM \; \;Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
3/26 - 8:00 AM \; \;Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
3/19 - 12:20 PM \; \;Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
3/13 - 8:00 AM \; \;Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
2/26 - 11:30 PM \; \;Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
2/26 - 7:01 AM \; \;Championing Rare Voices on Rare Disease Day
2/12 - 8:00 AM \; \;FDA Approves Takeda\'s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
2/8 - 6:00 PM \; \;Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
2/1 - 6:01 AM \; \;Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
2/1 - 1:54 AM \; \;Takeda Announces Chief Financial Officer Succession
2/1 - 1:02 AM \; \;Takeda Announces Third-Quarter FY2023 Results\; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth &\; Launch Products
1/31 - 4:11 PM \; \;Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
1/31 - 4:07 PM \; \;Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
1/29 - 11:10 AM \; \;Takeda\'s GAMMAGARD LIQUID Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
more news
\n'); } if (!allow) { document.write(''+ ''+ '

Access Denied

'+ '

Please Read This Important Message

'+ ' If you are a paying TickerTech.com client and your account was not set up to include the configuration'+ ' received, please email support@tickertech.com,'+ ' or call us at 1-866-515-2082 to verify your account settings.'+ ' '+ '

'+ ' '+ ' Note! If you reached this page'+ ' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+ ' paying client. For pricing information please visit our products page, email '+ ' services@tickertech.com, or give us a call at 1-866-515-2082.'+ ' '+ '

'+ ' '+ ' TickerTech.com home
'+ ' TickerTech.com products'+ '
'+ ' '+ ''); } }